A Phase 3 interventional study of Cagrilintide and Semaglutide in Cardiovascular Disease, sponsored by Novo Nordisk A/S. Active, not recruiting at 633 sites in 25 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.
5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.
This study's enrollment of 7,101 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Established CVD as evidenced by at least one of the following:
Symptomatic peripheral arterial disease (PAD) defined as at least one of the following:
For participants with T2D at screening the following inclusion criteria also apply:
Treatment with either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive cagrilintide and semaglutide subcutaneously (s.c.) once-weekly after a dose escalation period of 16 weeks during the maintenance period of 219 weeks.
Drug: Cagrilintide · Drug: Semaglutide
Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide s.c. once weekly for 235 weeks.
Drug: Placebo
Participants will receive cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
Participants will receive semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.
Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke
Measured in days.
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of a composite endpoint: Onset of persistent ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy, Kidney death and CV death
CKD-EPI is Chronic Kidney Disease Epidemiology Collaboration. Measured in days.
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of composite endpoint consisting of: Onset of persistent macro albuminuria, ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy and kidney death
CKD-EPI is Chronic Kidney Disease Epidemiology Collaboration. Measured in days.
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of an expanded 5-point MACE composite endpoint consisting of: CV death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation and unstable angina requiring hospitalisation
Measured in days.
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of a composite endpoint consisting of: all-cause death, non-fatal myocardial infarction and non-fatal stroke
Measured in days.
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of myocardial infarction (fatal and non-fatal)
Measured in days.
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of stroke (fatal and non-fatal)
Measured in days.
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Change in eGFRcr (CKD-EPI)
Measured in milliliter per min per 1.73 square meter (mL/min/1.73m\^2).
Time frame: From baseline (week 0) to 120 weeks
Ratio to baseline in Urine albumin-to-creatinine ratio (UACR)
Measured in ratio.
Time frame: From baseline (week 0) to 120 weeks
Relative change in body weight
Measured in percentage (%).
Time frame: From baseline (week 0) to 120 weeks
Change in waist circumference
Measured in centimeters (cm).
Time frame: From baseline (week 0) to 120 weeks
Change in waist-to-height ratio
Measured in ratio.
Time frame: From baseline (week 0) to 120 weeks
Change in systolic blood pressure (SBP)
Measured in millimeters of mercury (mmHg).
Time frame: From baseline (week 0) to 120 weeks
Change in diastolic blood pressure (DBP)
Measured in mmHg.
Time frame: From baseline (week 0) to 120 weeks
Ratio to baseline in lipids: Total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids
Measured in ratio.
Time frame: From baseline (week 0) to 120 weeks
Change in glycated haemoglobin (HbA1c)
Measured in percentage-points.
Time frame: From baseline (week 0) to 120 weeks
Number of treatment emergent serious adverse events (TESAEs)
Measured in count of events.
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Number of event adjudication committee (EAC)-confirmed malignant neoplasms
Measured as count of events.
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Number of severe hypoglycaemic episodes (level 3) (only for participants with type 2 diabetes mellitus [T2D] at screening)
Measured as count of events.
Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Showing the first 100 of 633 sites across 25 countries. Choose a country and city above to see the rest.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Sep 2027, 54 months after the start.
Of 42 industry-sponsored phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 79. This study's planned 54 months is above that.
Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide